DrugPatentWatch Database Preview
OPTIRAY 160 Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
When do Optiray 160 patents expire, and when can generic versions of Optiray 160 launch?
Optiray 160 is a drug marketed by Liebel-flarsheim and is included in one NDA.
The generic ingredient in OPTIRAY 160 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.
Summary for OPTIRAY 160
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 48 |
| Clinical Trials: | 1 |
| Patent Applications: | 860 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | OPTIRAY 160 at DailyMed |
Recent Clinical Trials for OPTIRAY 160
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mallinckrodt | Phase 4 |
Pharmacology for OPTIRAY 160
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
Synonyms for OPTIRAY 160
| 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide |
| 1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo- |
| 771I402 |
| 8771-40-2 |
| 87771-40-2 |
| AB00513943 |
| AB00513943_02 |
| AC-536 |
| AC1L1GLW |
| AC1Q4PBO |
| AKOS015896385 |
| AMDBBAQNWSUWGN-UHFFFAOYSA-N |
| AN-15742 |
| API0003020 |
| AS-12851 |
| BC215938 |
| BCP11109 |
| BPBio1_001051 |
| BRD-A65818372-001-01-2 |
| BRN 7155654 |
| BSPBio_000955 |
| C18H24I3N3O9 |
| CAS-87771-40-2 |
| CCG-213209 |
| CHEBI:31717 |
| CHEMBL1200614 |
| CS-7483 |
| CTK3E8473 |
| D01555 |
| DB09134 |
| DSSTox_CID_25521 |
| DSSTox_GSID_45521 |
| DSSTox_RID_80927 |
| DTXSID2045521 |
| FT-0627284 |
| HMS1570P17 |
| HMS2097P17 |
| HMS3714P17 |
| HY-B1410 |
| I06-1983 |
| ioversol |
| Ioversol (JAN/USP/INN) |
| Ioversol [USAN:INN:BAN] |
| Ioversol [USAN:USP:INN:BAN] |
| Ioversolum |
| Ioversolum [Latin] |
| LOVERSOL |
| LS-29726 |
| MolPort-005-938-391 |
| MP 328 |
| MP-328 |
| N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide |
| N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamide |
| N,N'-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)(2-hydroxyethyl)amino]-2-1,3-benzenedicarboxamide |
| n,n'-bis(2,3-dihydroxypropyl)-5-[glycoloyl(2-hydroxyethyl)amino]-2,4,6-triiodoisophthalamide |
| N1,N3-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-(2-hydroxyethyl)acetamido)-2,4,6-triiodoisophthalamide |
| N1,N3-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodo-benzene-1,3-dicarboxamide |
| N3RIB7X24K |
| NCGC00016956-01 |
| NCGC00179364-01 |
| NCGC00179364-03 |
| NSC-760064 |
| NSC760064 |
| Optiray |
| Optiray (TN) |
| Optiray 240 |
| Optiray 300 |
| Optiray 320 |
| Optiray 350 |
| P 530 |
| Pharmakon1600-01503837 |
| Prestwick0_000878 |
| Prestwick1_000878 |
| Prestwick2_000878 |
| Prestwick3_000878 |
| Q-201247 |
| SCHEMBL24711 |
| SPBio_002876 |
| SR-01000872680 |
| SR-01000872680-1 |
| Tox21_110709 |
| Tox21_110709_1 |
| UNII-N3RIB7X24K |
US Patents and Regulatory Information for OPTIRAY 160
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIRAY 160 | ioversol | INJECTABLE;INJECTION | 019710-003 | Dec 30, 1988 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPTIRAY 160
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIRAY 160 | ioversol | INJECTABLE;INJECTION | 019710-003 | Dec 30, 1988 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
